PRESS RELEASES

All Releases
Nov 12, 2018
AUSTIN, Texas , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it has petitioned the Food & Drug Administration ( FDA ) regarding a Complete Response Letter (CRL) for REMOXY issued August 2018.  The FDA and the Company
Oct 29, 2018
- Phase IIa Study Initiation On-track for Q4 2018 - AUSTIN, Texas , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today reported financial results for the third quarter ended September 30 , 2018.  Net loss was $1.3 million , or $0.11 per
Oct 23, 2018
Call to be held on Monday, October 29th at 4:30 p.m. Eastern Time AUSTIN, Texas , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, announced today it will release third quarter 2018 financial results, and hold a conference call with a Q&A
Oct 11, 2018
AUSTIN, Texas , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that Mr. Eric Schoen will join its management team as Chief Financial Officer, effective on or before November 7, 2018 .
Oct 04, 2018
– NIH Grant Will Enable Clinical Tests of PTI-125 in Patients with Alzheimer’s Disease – – Phase II Study Initiation Expected Q4 2018 – AUSTIN, Texas , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it has been awarded an
Oct 02, 2018
Call to be Held on Thursday, October 4th, 10:00 AM Eastern Time AUSTIN, Texas , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it will host a live conference call to provide a strategic update regarding its business, its
Aug 17, 2018

AUSTIN, Texas , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced the closing of its previously announced registered direct offering of 8,860,778 shares of its common stock, which was priced at-the-market at a purchase price of

Aug 16, 2018

– Proceeds to Be Used for Drug Development, General Corporate Purpose – AUSTIN, Texas , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional investors for the

Aug 15, 2018
– NIH Grant will Support Clinical Testing of PTI-125 – – Initiation of Phase II Study Expected Q4 2018 – AUSTIN, Texas , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today announced that the National Institutes of Health (NIH) has awarded
Aug 06, 2018

- Corporate Reorganization Expected Shortly - AUSTIN, Texas , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) for its New Drug Application (NDA) for REMOXY,